Brokerages Set Blueprint Medicines Corp (BPMC) PT at $103.25
Blueprint Medicines Corp (NASDAQ:BPMC) has earned an average recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $103.25.
A number of analysts have recently commented on BPMC shares. ValuEngine downgraded Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 24th. BidaskClub raised shares of Blueprint Medicines from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Thursday, November 15th. Zacks Investment Research raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Wednesday, January 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $103.00 price target on shares of Blueprint Medicines in a research report on Monday, January 7th.
Shares of BPMC stock traded down $3.05 on Friday, reaching $74.15. 1,686 shares of the stock were exchanged, compared to its average volume of 263,538. The company has a market cap of $3.30 billion, a price-to-earnings ratio of -18.91 and a beta of 1.61. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.03. Blueprint Medicines has a 1-year low of $44.58 and a 1-year high of $109.00.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Recommended Story: Municipal Bonds
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.